BeiGene's Brukinsa Drug Recommended for EU Authorization
September 19 2022 - 7:30AM
Dow Jones News
By Sabela Ojea
BeiGene Ltd. said Monday that a European Medicines Agency
committee has recommended granting marketing authorization for its
Brukinsa drug, aimed at treating adults diagnosed with a marginal
zone lymphoma.
The biotechnology company said the European Union's Committee
for Medicinal Products for Human Use has a positive opinion on the
Brukinsa inhibitor.
"With this positive opinion, we are one step closer to bringing
forward a chemotherapy-free treatment option for this rare blood
cancer," said Mehrdad Mobasher, BeiGene's chief medical officer of
hematology.
Marginal zone lymphoma is a group of ultra-rare, slow growing
B-cell malignancies that begin in the marginal zones of lymph
tissue. BeiGene said the incidence rate is estimated to range
between 20 million and 30 per million a year.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 19, 2022 08:15 ET (12:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024
